Chief Medical Officer · Janux Therapeutics, Inc. (JANX)

Wayne Godfrey

FY2021 is the first fiscal year CompBrief holds for Wayne Godfrey as a named executive officer of Janux Therapeutics; the record below is that year, complete. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2021

$4,277,949

Salary $257,045Stock awards $0

2nd of 3 named executive officers at Janux Therapeutics by FY2021 total.

3 named officers on file for Janux Therapeutics, FY2021

Wayne Godfrey’s pay file — $29

  • 1 fiscal year of pay, line by line
  • 1 equity grant, each cited to its filing
  • JANX’s disclosed peer group of 16 companies

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how Janux Therapeutics’s whole pay program stands against its peers

  • Janux Therapeutics’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on JANX→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 29, 2022 (DEF 14A). Insider transactions since that proxy, current to 2026-11-21.

Free

Get Wayne Godfrey’s pay history as a PDF, right here and by email

The PDF adds what this page leaves out: up to 10 years of pay, a peer comparison, and the board on one page. Two emails at most, nothing else.

Wayne Godfrey compensation by year

Janux Therapeutics Summary Compensation Table · the one fiscal year held
In US dollars, as Janux Therapeutics reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2021
Salary$257,045
Bonus$0
Stock awards$0
Option awards$3,918,086
Non-equity incentive$102,818
Pension and deferred compensation$0
All other$0
Total$4,277,949

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Janux Therapeutics, Inc. DEF 14A filed April 29, 2022, accession 0000950170-22-006742, and prior-year filings. Open the filing on EDGAR.

How this page was built: the Janux Therapeutics, Inc. filed document, accession 0000950170-22-006742. Every figure is read from that document and cited to the page and table it appears in. Filed April 29, 2022.

Insider transactions since the last proxy

1 Form 4 line since the FY2021 proxy (filed April 29, 2022)
current to 2026-11-21 · updated nightly
DateTransactionPlanSharesPriceHeld after
2023-01-03Grant or award derivative—110,000$0.00110,000

The 1 most recent of 1 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →

Janux Therapeutics’s named executive officers, FY2021

as the company reported each
Named executive officerRoleFY2021 total
David CampbellPresident and Chief Executive Officer$8,410,429
Wayne Godfrey · this pageChief Medical Officer$4,277,949
Shahram Salek-ArdakaniChief Scientific Officer$4,009,435

The full Janux Therapeutics compensation record

free company brief

This page is one person within Janux Therapeutics's record. The company brief lists every named executive, each linking to their own page.

Peer companies

named in the Janux Therapeutics proxy · each links to its own free brief

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Janux Therapeutics's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Wayne Godfrey's compensation dossier · One-time report. No refunds.